



MR CLEAN KEY FINDINGS

STUDY PURPOSE: In patients with acute ischemic stroke caused by proximal intracranial arterial occlusion, intra-arterial treatment (IAT) is highly effective for emergent revascularization. 500 patients with a proximal arterial occlusion in the anterior cerebral circulation demonstrated on vessel imaging, treated with IAT within 6 hours were randomized to IAT plus usual care (IV t-PA or medical management) or usual care alone.



PREDOMINANTLY STENT RETRIEVERS INCLUDING THE SOLITAIRE™ DEVICE USED FOR INTERVENTIONAL THERAPY.





**A randomized trial of
intra-arterial treatment
for acute stroke**

NO SIGNIFICANT DIFFERENCE IN BASELINE CHARACTERISTICS BETWEEN STUDY ARMS:


| CHARACTERISTIC | INTERVENTION** (n=233) | CONTROL (n=266) | |
|---|---------------------------|------------------------|-----------------|
| Age in years - median (Interquartile range, IQR) | 65.8 (54.5 to 76.0) | 65.7 (55.5 to 76.4) | |
| Male sex - n (%) | 135 (57.9%) | 157 (58.8%) | |
| NIHSS score - median (IQR; range) | 17 (14 to 21; 3 to 30) | 18 (14 to 22; 4 to 38) | |
| Treatment with IV alteplase - n (%) | 203 (87.1%) | 242 (90.6%) | |
| Time from onset to start of IV alteplase - minutes median (IQR) | 85 (67 to 110) | 87 (65 to 116) | |
| INTRACRANIAL ARTERIAL OCCLUSION LOCATION | ICA - n (%) | 1 (0.4%) | 3/266 (1.1%) |
| | ICA - T - n (%) | 59 (25.3%) | 75/266 (28.2%) |
| | M1 segment - n (%) | 154 (66.1%) | 165/266 (62.0%) |
| | M2 segment - n (%) | 18 (7.7%) | 21/266 (7.9%) |
| | A1/2 segment - n (%) | 1 (0.4%) | 2/266 (0.8%) |
| Time from onset to randomization - minutes median (IQR) | 204 (152 to 251) | 196 (149 to 266) | |
| Time from onset to groin puncture - minutes median (IQR) | 260 (210 to 313) | NA | |

SIGNIFICANT IMPROVEMENT IN FUNCTIONAL OUTCOMES AT 90 DAYS OBSERVED WITH THE ADDITION OF INTERVENTIONAL THERAPY.

| OUTCOME | ADJUSTED EFFECT (aOR, 95%CI) |
|---------|------------------------------|
| mRS 0-1 | 2.1 (1.1 to 4.0) |
| mRS 0-2 | 2.2 (1.4 to 3.4) |
| mRS 0-3 | 1.9 (1.4 to 3.0) |
| mRS 0-4 | 1.5 (1.0 to 2.4) |
| mRS 0-5 | 1.1 (0.7 to 1.7) |



NO SIGNIFICANT DIFFERENCE IN MORTALITY OUT TO 90 DAYS.



STUDY CONCLUSION:

The MR CLEAN study observed that the addition of stent thrombectomy for acute ischemic stroke care is safe and effective when administered within 6 hours of symptom onset.

Medtronic

9775 Toledo Way
Irvine, CA 92618
USA
Tel 877.526.7890
Fax 763.526.7888

medtronic.com/SoliFacts

* Solitaire™ FR Revascularization Device used in Intervention group ** Merci Retriever® used in Intervention group

SOURCE: Berkhemer OA, Fransen PS, Beumer D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N. Engl. J. Med. Jan 1 2015;372(1):11-20.

CAUTION: Federal (USA) law restricts these devices to sale distribution and use by or on order of a physician. Indications, contraindications, warnings and instructions for use for Solitaire™ X Revascularization Device can be viewed at www.medtronic.com/manuals

© 2019 Medtronic. All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. All other brands are trademarks of a Medtronic company. UC201908415 EN